New imaging tracer shows promise for spotting GVHD without biopsy
NCT ID NCT03367962
First seen Dec 12, 2025 · Last updated May 22, 2026 · Updated 21 times
Summary
This early-phase study tested a new imaging tracer called [18F]F-AraG in 9 patients to see if it could detect graft-versus-host disease (GVHD) after a stem cell transplant. The tracer highlights activated immune cells that cause GVHD, and the scans were compared with standard biopsies. The goal was to find a less invasive way to diagnose and monitor GVHD. Because the study was small and focused on imaging, it does not offer a treatment or cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT-VERSUS-HOST-DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Stanford Hospital
Stanford, California, 94305, United States
Conditions
Explore the condition pages connected to this study.